GSK will be introducing its fixed-dose ‘Avodart(dutasteride)’ and tamsulosin combination for the treatment of prostatic hyperplasia for the first time in Korea. The domestic approval has come 10 years after the approval by EMA and FDA.

Considering that the combined prescription of the abovementioned two drugs is common in the prostatic hyperplasia treatment market, whether the introduction of this combination drug will change the market structure is the focus of interest.

The Ministry of Food and Drug Safety (MFDS) granted GSK’s ‘Duodart capsule’ marketing approval on the 18th. Duodart capsule is a fixed-dose combination of dutasteride and tamsulosin used for the treatment of moderate-t